Ligand Discrimination in Immune Cells: Signal Processing Insights into Immune Dysfunction in ER+ Breast Cancer
Uloženo v:
| Vydáno v: | bioRxiv (Feb 17, 2025) |
|---|---|
| Hlavní autor: | |
| Další autoři: | , , , , , , |
| Vydáno: |
Cold Spring Harbor Laboratory Press
|
| Témata: | |
| On-line přístup: | Citation/Abstract Full text outside of ProQuest |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3167783936 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2692-8205 | ||
| 024 | 7 | |a 10.1101/2025.02.15.638458 |2 doi | |
| 035 | |a 3167783936 | ||
| 045 | 0 | |b d20250217 | |
| 100 | 1 | |a Matache, Adina | |
| 245 | 1 | |a Ligand Discrimination in Immune Cells: Signal Processing Insights into Immune Dysfunction in ER+ Breast Cancer | |
| 260 | |b Cold Spring Harbor Laboratory Press |c Feb 17, 2025 | ||
| 513 | |a Working Paper | ||
| 520 | 3 | |a Prior studies have shown that approximately 40% of estrogen receptor positive (ER+) breast cancer (BC) patients harbor immune signaling defects in their blood at diagnosis, and the presence of these defects predicts overall survival. Therefore, it is of interest to quantitatively characterize and measure signaling errors in immune signaling systems in these patients. Here we propose a novel approach combining communication theory and signal processing concepts to model ligand discrimination in immune cells in the peripheral blood. We use the model to measure the specificity of ligand discrimination in the presence of molecular noise by estimating the probability of error, which is the probability of making a wrong ligand identification. We apply our model to the JAK/STAT signaling pathway using high dimensional spectral flow cytometry measurements of transcription factors, including phosphorylated STATs and SMADs, in immune cells stimulated with several cytokines (IFNγ, IL-2, IL-6, IL-4, and IL-10) from 19 ER+ breast cancer patients and 32 healthy controls. In addition, we apply our model to 10 healthy donor samples treated with a clinically approved JAK1/2 inhibitor. Our results show reduced ligand identification accuracy and higher levels of molecular noise in BC patients as compared to healthy controls, which may indicate altered immune signaling and the potential for immune cell dysfunction in these patients. Moreover, the inhibition of JAK1/2 produces ligand misidentification and molecular noise rates similar to, or even greater than, those observed in breast cancer. These results suggest a means to improve the use of signaling kinase inhibitor therapies by identifying patients with favorable ligand discrimination specificity profiles in their immune cells.Competing Interest StatementThe authors have declared no competing interest. | |
| 653 | |a Signal processing | ||
| 653 | |a Janus kinase | ||
| 653 | |a Ligands | ||
| 653 | |a Breast cancer | ||
| 653 | |a Transcription factors | ||
| 653 | |a Cell interactions | ||
| 653 | |a Peripheral blood | ||
| 653 | |a Flow cytometry | ||
| 653 | |a Estrogen receptors | ||
| 653 | |a Interleukins | ||
| 653 | |a γ-Interferon | ||
| 653 | |a Signal transduction | ||
| 653 | |a Cell survival | ||
| 700 | 1 | |a Lima, Joao Rodrigues, Jr | |
| 700 | 1 | |a Kuznetsov, Maxim | |
| 700 | 1 | |a Urbaniak, Konstancja | |
| 700 | 1 | |a Branciamore, Sergio | |
| 700 | 1 | |a Rodin, Andrei | |
| 700 | 1 | |a Lee, Peter P | |
| 700 | 1 | |a Rockne, Russell C | |
| 773 | 0 | |t bioRxiv |g (Feb 17, 2025) | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3167783936/abstract/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full text outside of ProQuest |u https://www.biorxiv.org/content/10.1101/2025.02.15.638458v1 |